CoChat

The Anti-Androgen Hydroxyflutamide and Androgens Inhibit Interleukin-6 Production by an Androgen-Responsive Human Osteoblastic Cell Line

Hofbauer, Lorenz C., Ten, Rosa M., Khosla, Sundeep · 1999 · Journal of Bone and Mineral Research
Cited by 77

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

While androgens clearly have significant skeletal effects, the paracrine mediators of androgen action on bone are at present unclear. Interleukin-6 (IL-6) is a candidate cytokine that is produced by osteoblastic lineage cells and promotes osteoclastogenesis and bone resorption. Here, we assessed constitutive as well as IL-1β– and tumor necrosis factor-α (TNF-α)–stimulated IL-6 mRNA expression by Northern analysis and protein secretion by immunoassay in a human androgen-responsive osteoblastic cell line (hFOB/AR-6) which contains ∼4000 androgen receptors (ARs)/nucleus. Treatment with 5α-dihydrotestosterone (DHT) dose-dependently inhibited constitutive and TNF-α/IL-1β–stimulated IL-6 mRNA steady-state levels in hFOB/AR-6 cells by 70–80% at 10−7 M. In addition, testosterone also suppressed TNF-α/IL-1β–stimulated IL-6 mRNA levels by 57%, while the adrenal androgen dehydroepiandrosterone had no effect. Of note, the specific AR antagonist, hydroxyflutamide, also inhibited IL-6 mRNA levels by 70%. Consistent with the Northern analyses, treatment with 5α-DHT, testosterone, and hydroxyflutamide also inhibited IL-6 protein production by 79%, 62%, and 71%, respectively (p < 0.001), while these agents had no effect on IL-6 soluble receptor levels. Finally, we demonstrated that hydroxyflutamide treatment of hFOB/AR-6 cells markedly inhibited the activation and binding of NF-κB (a known stimulator of IL-6 gene transcription) to its response element, thus providing a potential mechanism for its effect on IL-6 production by osteoblasts. These data are consistent with the hypothesis that suppression of osteoblast IL-6 production by androgens may mediate, at least in part, the antiresorptive effects of androgens on bone. Moreover, our findings also indicate that hydroxyflutamide, which is a known AR antagonist in most tissues, may function as a selective AR modulator for effects on IL-6 production by osteoblasts.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1359/jbmr.1999.14.8.1330

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 37

  1. Orwoll, 1995, Osteoporosis in men, Endocr Rev, 16, 87, 10.1210/edrv-16-1-87 · DOI · Paper page
  2. Turner, 1994, Skeletal effects of estrogen, Endocr Rev, 15, 275
  3. Bagatell, 1996, Androgens in men: Uses and abuses, N Engl J Med, 334, 707, 10.1056/NEJM199603143341107 · DOI · Paper page
  4. Horowitz, 1993, Cytokines and estrogen in bone: Anti-osteoporotic effects, Science, 260, 626, 10.1126/science.8480174 · DOI · Paper page
  5. Vanderschueren, 1995, Androgens and bone, Calcif Tissue Int, 56, 341, 10.1007/BF00301598 · DOI
  6. Chang, 1988, Molecular cloning of human and rat complementary DNA encoding androgen receptors, Science, 240, 324, 10.1126/science.3353726 · DOI · Paper page
  7. Lubahn, 1988, The human androgen receptor: Complementary deoxyribonucleic acid cloning, sequence analysis and gene expression in prostate, Mol Endocrinol, 2, 1265, 10.1210/mend-2-12-1265 · DOI · Paper page
  8. Bellido, 1995, Regulation of interleukin-6, osteoclastogenesis, bone mass by androgens: The role of the androgen receptor, J Clin Invest, 95, 2886, 10.1172/JCI117995 · DOI · Paper page
  9. Mizuno, 1994, Immunocytochemical identification of androgen receptor in mouse osteoclast-like multinucleated cells, Calcif Tissue Int, 54, 325, 10.1007/BF00295958 · DOI
  10. Manolagas, 1995, Bone marrow, cytokines, and bone remodeling: Emerging insights into the pathophysiology of osteoporosis, N Engl J Med, 332, 305, 10.1056/NEJM199502023320506 · DOI · Paper page
  11. Passeri, 1993, Increased interleukin-6 production by murine bone marrow and bone cells after estrogen withdrawal, Endocrinology, 133, 822, 10.1210/endo.133.2.8393776 · doi:10.1210/endo.133.2.8393776 · Paper page
  12. Girasole, 1992, 17β-Estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: A potential mechanism for the antiosteoporotic effect of estrogens, J Clin Invest, 89, 883, 10.1172/JCI115668 · DOI · Paper page
  13. Jilka, 1992, Increased osteoclast development after estrogen loss: Mediation by interleukin-6, Science, 257, 88, 10.1126/science.1621100 · DOI · Paper page
  14. Kassem, 1996, Estrogen inhibits interleukin-6 production and gene expression in a human osteoblastic cell line with high levels of estrogen receptors, J Bone Miner Res, 11, 193, 10.1002/jbmr.5650110208 · DOI · Paper page
  15. Poli, 1994, Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion, EMBO J, 13, 1189, 10.1002/j.1460-2075.1994.tb06368.x · DOI · Paper page
  16. Pottratz, 1994, 17β-estradiol inhibits expression of human interleukin-6 promoter-reporter constructs by a receptor-dependent mechanism, J Clin Invest, 93, 944, 10.1172/JCI117100 · DOI · Paper page
  17. Ray, 1994, Down-modulation of interleukin-6 gene expression by 17β-estradiol in the absence of high affinity DNA binding by the estrogen receptor, J Biol Chem, 269, 12940, 10.1016/S0021-9258(18)99966-7 · DOI · Paper page
  18. Barnes, 1997, Nuclear factor-κB—A pivotal transcription factor in chronic inflammatory diseases, N Engl J Med, 336, 1066, 10.1056/NEJM199704103361506 · DOI · Paper page
  19. Hofbauer, 1997, Development and characterization of a conditionally immortalized human osteoblastic cell line stably transfected with the human androgen receptor gene, J Cell Biochem, 66, 442, 10.1002/(SICI)1097-4644(19970915)66:4<542::AID-JCB13>3.0.CO;2-D · doi:10.1002/(sici)1097-4644(19970915)66:4<542::aid-jcb13>3.0.co;2-d
  20. Hofbauer, 1998, Effects of gonadal and adrenal androgens in a novel androgen-responsive human osteoblastic cell line, J Cell Biochem, 71, 96, 10.1002/(SICI)1097-4644(19981001)71:1<96::AID-JCB10>3.0.CO;2-G · DOI · Paper page
  21. Harris, 1995, Development and characterization of a conditionally immortalized human fetal osteoblastic cell line, J Bone Miner Res, 10, 178, 10.1002/jbmr.5650100203 · DOI · Paper page
  22. Bradford, 1976, A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding, Anal Biochem, 72, 248, 10.1016/0003-2697(76)90527-3 · DOI · Paper page
  23. Lehrach, 1977, RNA molecular weight determinations by gel electrophoresis under denaturing conditions, a critical reexamination, Biochemistry, 16, 4743, 10.1021/bi00640a033 · DOI · Paper page
  24. Thomas, 1980, Hybridization of denatured RNA and small DNA fragments transferred to nitrocellulose, Proc Natl Acad Sci USA, 77, 5201, 10.1073/pnas.77.9.5201 · DOI · Paper page
  25. Herrin, 1988, Rapid, reversible staining of Northern blots prior to hybridization, BioTechniques, 6, 196
  26. Feinberg, 1983, A technique for radiolabelling DNA restriction endonuclease fragments to high specific activity, Anal Biochem, 132, 6, 10.1016/0003-2697(83)90418-9 · DOI · Paper page
  27. Yang, 1995, Fast hybridization solution for the detection of immobilized nucleic acids, BioTechniques, 18, 498
  28. Dignam, 1983, Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei, Nucleic Acids Res, 5, 1475, 10.1093/nar/11.5.1475 · DOI · Paper page
  29. Breuninger, 1993, Hydrocortisone regulation of interleukin-6 protein production by a purified population of human peripheral blood monocytes, Clin Immunol Immunopathol, 69, 205, 10.1006/clin.1993.1171 · DOI
  30. Harris, 1995, Estrogen response in the hFOB 1.19 human fetal osteoblastic cell line stably transfected with the human estrogen receptor gene, J Cell Biochem, 59, 193, 10.1002/jcb.240590209 · DOI
  31. Simard, 1997, Comparison of in vitro effects of the pure antiandrogen OH-flutamide, casodex, and nilutamide on androgen-sensitive parameters, Urology, 49, 580, 10.1016/S0090-4295(97)00029-0 · DOI
  32. McDonnell, 1997, Analysis of the molecular pharmacology of estrogen receptor agonists and antagonists provides insights into the mechanism of action of estrogen in bone, Osteoporos Int, 7, S29, 10.1007/BF01674810 · DOI
  33. Stein, 1995, Repression of the interleukin-6 promoter by estrogen receptor is mediated by NF κB and C/EPBβ, Mol Cell Biol, 15, 4971, 10.1128/MCB.15.9.4971 · DOI · Paper page
  34. Goulding, 1993, Flutamide-mediated androgen blockade evokes osteopenia in the female rat, J Bone Miner Res, 8, 763, 10.1002/jbmr.5650080615 · DOI
  35. Bertelloni, 1997, Androgen-receptor blockade does not impair bone mineral density in adolescent females, Calcif Tissue Int, 61, 1, 10.1007/s002239900282 · DOI
  36. Zhang, 1998, Orchiectomy increases bone marrow interleukin-6 levels in mice, Calcif Tissue Int, 62, 219, 10.1007/s002239900421 · DOI
  37. Giuliani, 1998, Bisphosphonates inhibit IL-6 production by human osteoblast-like cells, Scand J Rheumatol, 27, 38, 10.1080/030097498441155 · DOI · Paper page

Cited by

See all 77

Metadata

Authors
Hofbauer, L. C., Ten, R. M., & Khosla, S.
Venue
Journal of Bone and Mineral Research
Published
1999-08-01
Volume
14
Issue
8
Pages
1330-1337
ISSN
  • 0884-0431 (ISSN-L)
  • 1523-4681
OpenAlex
W2039342183
Cited by
77
References
2
FWCI
1.85
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Anti-Androgen Hydroxyflutamide and Androgens Inhibit Interleukin-6 Production by an Androgen-Responsive Human Osteoblastic Cell Line. https://app.cochat.ai/papers/10.1359/jbmr.1999.14.8.1330
The paper
Hofbauer, L. C., Ten, R. M., & Khosla, S. (1999). The Anti-Androgen Hydroxyflutamide and Androgens Inhibit Interleukin-6 Production by an Androgen-Responsive Human Osteoblastic Cell Line. Journal of Bone and Mineral Research. https://doi.org/10.1359/jbmr.1999.14.8.1330

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.